USFDA completes inspection of Zydus Lifesciences with zero observations

The USFDA inspection is a crucial step in ensuring compliance with international quality standards and regulations.

180
USFDA Inspection
USFDA Inspection

Last Updated on November 11, 2024 by The Health Master

Zydus Lifesciences has informed stock exchanges that its animal health drug manufacturing facility in the Ahmedabad Special Economic Zone (SEZ) has cleared an inspection by the United States Food and Drug Administration (USFDA).

The inspection, which took place from May 30 to June 2, concluded without any observations or concerns raised. 

The USFDA inspection is a crucial step in ensuring compliance with international quality standards and regulations.

On June 2, the Zydus Lifesciences share price closed at Rs 518, 0.9 percent higher from the closing price of Rs 513 the previous day.

For the quarter ended March 2023, Zydus Lifesciences reported a 25.36 percent decline in consolidated net profit at Rs 296.6 crore impacted by impairment of goodwill of a wholly-owned subsidiary.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news